NCT05991427 - A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

November 4, 2024

Study Completion Date

November 4, 2024

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)

2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4

BIOLOGICAL

Zoster Vaccine Recombinant, Adjuvanted (Shingrix)

2 doses of Shingrix vaccine on Day 0 and Month 4

BIOLOGICAL

ChAdOx1-VZV

2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4

BIOLOGICAL

Shingrix

2 doses of Shingrix vaccine on Day 0 and Month 4

BIOLOGICAL

IH ChAdOx1-VZV

2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4

BIOLOGICAL

IH saline

2 doses of saline on Day 0 and Month 4

Trial Locations (1)

Canadian Center for Vaccinology, Halifax